Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. The aim of this study was to report the long-term safety of secukinumab in pooled data from 28 cli...

Descripción completa

Detalles Bibliográficos
Autores principales: GOTTLIEB, Alice B., DEODHAR, Atul, MCINNES, Iain B., BARALIAKOS, Xenofon, REICH, Kristian, SCHREIBER, Stefan, BAO, Weibin, MARFO, Kwaku, RICHARDS, Hanno B., PRICOP, Luminita, SHETE, Abhijit, TRIVEDI, Vivek, KEEFE, Deborah, PAPAVASSILIS, Charis C., JAGIELLO, Piotr, PAPANASTASIOU, Philemon, MEASE, Philip J., LEBWOHL, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631291/
https://www.ncbi.nlm.nih.gov/pubmed/35146532
http://dx.doi.org/10.2340/actadv.v102.563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631291/
https://www.ncbi.nlm.nih.gov/pubmed/35146532
http://dx.doi.org/10.2340/actadv.v102.563

Ejemplares similares